Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsUpgradesPrice Target
Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.